115 related articles for article (PubMed ID: 11313940)
1. A role for mismatch repair in control of DNA ploidy following DNA damage.
Strathdee G; Sansom OJ; Sim A; Clarke AR; Brown R
Oncogene; 2001 Apr; 20(15):1923-7. PubMed ID: 11313940
[TBL] [Abstract][Full Text] [Related]
2. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
3. Single cell tracking reveals that Msh2 is a key component of an early-acting DNA damage-activated G2 checkpoint.
Marquez N; Chappell SC; Sansom OJ; Clarke AR; Court J; Errington RJ; Smith PJ
Oncogene; 2003 Oct; 22(48):7642-8. PubMed ID: 14576827
[TBL] [Abstract][Full Text] [Related]
4. The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase.
Franchitto A; Pichierri P; Piergentili R; Crescenzi M; Bignami M; Palitti F
Oncogene; 2003 Apr; 22(14):2110-20. PubMed ID: 12687013
[TBL] [Abstract][Full Text] [Related]
5. Non-tumor cells from an MSH2-null individual show altered cell cycle effects post-UVB.
Narine KA; Felton KE; Parker AA; Tron VA; Andrew SE
Oncol Rep; 2007 Dec; 18(6):1403-11. PubMed ID: 17982623
[TBL] [Abstract][Full Text] [Related]
6. Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner.
Sansom OJ; Toft NJ; Winton DJ; Clarke AR
Oncogene; 2001 Jun; 20(27):3580-4. PubMed ID: 11429706
[TBL] [Abstract][Full Text] [Related]
7. The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice.
Sansom OJ; Clarke AR
Oncogene; 2002 Aug; 21(38):5934-9. PubMed ID: 12185594
[TBL] [Abstract][Full Text] [Related]
8. Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin.
Vernole P; Tedeschi B; Tentori L; Levati L; Argentin G; Cicchetti R; Forini O; Graziani G; D'Atri S
Mutat Res; 2006 Feb; 594(1-2):63-77. PubMed ID: 16139849
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous and mutagen-induced loss of DNA mismatch repair in Msh2-heterozygous mammalian cells.
Borgdorff V; van Hees-Stuivenberg S; Meijers CM; de Wind N
Mutat Res; 2005 Jul; 574(1-2):50-7. PubMed ID: 15914206
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 activates a G2-M cell cycle checkpoint following 6-thioguanine-induced DNA mismatch damage.
Yamane K; Schupp JE; Kinsella TJ
Cancer Res; 2007 Jul; 67(13):6286-92. PubMed ID: 17616687
[TBL] [Abstract][Full Text] [Related]
11. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB
Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458
[TBL] [Abstract][Full Text] [Related]
12. Ionizing radiation-induced apoptosis via separate Pms2- and p53-dependent pathways.
Zeng M; Narayanan L; Xu XS; Prolla TA; Liskay RM; Glazer PM
Cancer Res; 2000 Sep; 60(17):4889-93. PubMed ID: 10987303
[TBL] [Abstract][Full Text] [Related]
13. Mouse mismatch repair gene Msh2 is not essential for transcription-coupled repair of UV-induced cyclobutane pyrimidine dimers.
Sonneveld E; Vrieling H; Mullenders LH; van Hoffen A
Oncogene; 2001 Jan; 20(4):538-41. PubMed ID: 11313985
[TBL] [Abstract][Full Text] [Related]
14. A combination of MSH2 DNA mismatch repair deficiency and expression of the SV40 large T antigen results in cisplatin resistance of mouse embryonic fibroblasts.
Yasin SL; Rainbow AJ
Int J Oncol; 2011 Sep; 39(3):719-26. PubMed ID: 21667017
[TBL] [Abstract][Full Text] [Related]
15. DNA mismatch repair deficiency stimulates N-ethyl-N-nitrosourea-induced mutagenesis and lymphomagenesis.
Claij N; van der Wal A; Dekker M; Jansen L; te Riele H
Cancer Res; 2003 May; 63(9):2062-6. PubMed ID: 12727820
[TBL] [Abstract][Full Text] [Related]
16. Role of DNA mismatch repair in the cytotoxicity of ionizing radiation.
Fritzell JA; Narayanan L; Baker SM; Bronner CE; Andrew SE; Prolla TA; Bradley A; Jirik FR; Liskay RM; Glazer PM
Cancer Res; 1997 Nov; 57(22):5143-7. PubMed ID: 9371516
[TBL] [Abstract][Full Text] [Related]
17. Role of wild type p53 in the G2 phase: regulation of the gamma-irradiation-induced delay and DNA repair.
Schwartz D; Almog N; Peled A; Goldfinger N; Rotter V
Oncogene; 1997 Nov; 15(21):2597-607. PubMed ID: 9399647
[TBL] [Abstract][Full Text] [Related]
18. DNA mismatch repair proteins promote apoptosis and suppress tumorigenesis in response to UVB irradiation: an in vivo study.
Young LC; Thulien KJ; Campbell MR; Tron VA; Andrew SE
Carcinogenesis; 2004 Oct; 25(10):1821-7. PubMed ID: 15166087
[TBL] [Abstract][Full Text] [Related]
19. Immortalized mouse cell lines that lack a functional Rev3 gene are hypersensitive to UV irradiation and cisplatin treatment.
Zander L; Bemark M
DNA Repair (Amst); 2004 Jul; 3(7):743-52. PubMed ID: 15177183
[TBL] [Abstract][Full Text] [Related]
20. Methylation tolerance in mismatch repair proficient cells with low MSH2 protein level.
Claij N; Te Riele H
Oncogene; 2002 Apr; 21(18):2873-9. PubMed ID: 11973647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
